Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12444MR)

This product GTTS-WQ12444MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000878.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3560
UniProt ID P14784
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12444MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12814MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ4249MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ3818MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ681MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ5424MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ14664MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ1570MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ13904MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-2176
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW